|Education||BS, Duke University|
|Current Position||Postdoctoral Fellow|
Johns Hopkins University
The advent of highly active antiretroviral therapy (HAART) for the treatment of HIV-1 infection has significantly reduced the associated morbidity and mortality . However, a cure for HIV-1 infection remains elusive due to the stable persistence of the virus within a subset of resting memory CD4 T cells. This latent reservoir of dormant provirus is invisible to the host immune system and is extremely stable, requiring infected patients to remain on HAART indefinitely to prevent viral rebound. As such, this latent reservoir is the main barrier to a cure of HIV-1 infection. A number of compounds have been identified that can reactivate latent HIV-1, but the consequences of this reactivation in latently infected cells from HIV-1 infected patients is not fully understood. I am working to understand the effects of these compounds on the HIV-1 latent reservoir, as well as identify strategies to induce the death of these latently infected cells.